David J. Nutt mainly focuses on Psychiatry, Neuroscience, Anxiety, Pharmacology and Clinical psychology. His Psychiatry study frequently draws connections to other fields, such as Evidence-based practice. As a part of the same scientific study, David J. Nutt usually deals with the Neuroscience, concentrating on Psychedelic experience and frequently concerns with Psychedelic therapy, Functional magnetic resonance imaging, Default mode network and Resting state fMRI.
His work in Pharmacology tackles topics such as Benzodiazepine which are related to areas like GABAA receptor and Antagonist. His Panic disorder study also includes fields such as
His scientific interests lie mostly in Psychiatry, Pharmacology, Internal medicine, Anxiety and Endocrinology. Psychiatry is closely attributed to Clinical psychology in his study. His Pharmacology research incorporates elements of Agonist, Receptor and Benzodiazepine.
He does research in Internal medicine, focusing on Serotonin specifically. His study involves Anxiety disorder, Panic disorder and Generalized anxiety disorder, a branch of Anxiety. David J. Nutt interconnects Antagonist and Idazoxan in the investigation of issues within Endocrinology.
David J. Nutt spends much of his time researching Psychiatry, Neuroscience, Addiction, Clinical psychology and Pharmacology. Psychiatry is closely attributed to MEDLINE in his research. Many of his studies involve connections with topics such as Receptor and Neuroscience.
His Addiction research incorporates themes from Alcohol dependence, Endocrinology, Psychotherapist, Internal medicine and Criminology. His studies link Anxiety with Clinical psychology. His research in Psilocybin is mostly concerned with Psychedelic therapy.
David J. Nutt mainly investigates Psychiatry, Neuroscience, Clinical psychology, Addiction and Psilocybin. His Psychiatry research includes themes of Alternative medicine and Internal medicine. David J. Nutt focuses mostly in the field of Clinical psychology, narrowing it down to matters related to Anxiety and, in some cases, Biomarker and Neuroimaging.
His biological study spans a wide range of topics, including Alcohol, Alcohol dependence, Impulsivity, Dopamine and Opioid. His Psilocybin research integrates issues from Psychotherapist, Treatment-resistant depression and Mood. His Endogenous opioid research is multidisciplinary, relying on both Endocrinology and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Drug harms in the UK: a multicriteria decision analysis.
David J Nutt;Leslie A King;Lawrence D Phillips.
The Lancet (2010)
Development of a rational scale to assess the harm of drugs of potential misuse
David Nutt;Leslie A King;William Saulsbury;Colin Blakemore.
The Lancet (2007)
Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function.
Vassilios Papadopoulos;Mario Baraldi;Tomás R. Guilarte;Thomas B. Knudsen.
Trends in Pharmacological Sciences (2006)
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris;David Erritzoe;Tim Williams;James M. Stone.
Proceedings of the National Academy of Sciences of the United States of America (2012)
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
David S. Baldwin;Ian M. Anderson;David J. Nutt;Borwin Bandelow.
Journal of Psychopharmacology (2005)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris;Mark Bolstridge;James Rucker;Camilla M. J. Day.
The Lancet Psychiatry (2016)
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Robin Lester Carhart-Harris;Robert Leech;Peter John Hellyer;Murray Shanahan.
Frontiers in Human Neuroscience (2014)
British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.
S. J. Wilson;D. J. Nutt;C. Alford;S. V. Argyropoulos.
Journal of Psychopharmacology (2010)
Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety
James C. Ballenger;Jonathan R. T. Davidson;Yves Lecrubier;David J. Nutt.
The Journal of Clinical Psychiatry (2000)
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines:
I. M. Anderson;D. J. Nutt;J. F. W. Deakin.
Journal of Psychopharmacology (2000)
Journal of Psychopharmacology
(Impact Factor: 4.562)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: